Shares of Koninklijke Philips (NYSE:PHG – Get Free Report) have earned a consensus rating of “Hold” from the four brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and one has assigned a buy recommendation to the company.
A number of research analysts have recently weighed in on PHG shares. StockNews.com raised shares of Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. BNP Paribas cut shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research note on Wednesday, February 7th.
Institutional Trading of Koninklijke Philips
Koninklijke Philips Trading Up 0.2 %
Shares of Koninklijke Philips stock opened at $20.65 on Thursday. Koninklijke Philips has a 12-month low of $15.63 and a 12-month high of $24.27. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58. The stock has a market cap of $19.18 billion, a PE ratio of -36.23, a price-to-earnings-growth ratio of 0.96 and a beta of 0.90. The company has a 50-day moving average of $22.30 and a two-hundred day moving average of $21.13.
About Koninklijke Philips
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services.
- Five stocks we like better than Koninklijke Philips
- Dividend Tax Calculator
- 3 attractive stocks that insiders are buying
- Your Comprehensive Guide to Investing in Bank Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Stock Splits, Do They Really Impact Investors?
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Koninklijke Philips Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips and related companies with MarketBeat.com's FREE daily email newsletter.